SemaglutideTirzepatideRetatrutide
Property
Categoryglp1glp1glp1
Typepeptidepeptidepeptide
MechanismGLP-1 receptor agonistDual GLP-1/GIP receptor agonistTriple agonist (GLP-1/GIP/Glucagon)
Research Stagefda-approvedfda-approvedresearch
Dosing Range0.25-2.4mg weekly2.5-15mg weekly1-12mg weekly
FrequencyOnce weeklyOnce weeklyOnce weekly
Half-Life~7 days~5 days~6 days
Bioavailability / Route
Subcutaneous
Subcutaneous
Subcutaneous
Onset Time2-4 weeks for appetite reduction2-4 weeks for appetite reduction2-4 weeks
Key Benefits
Weight managementType 2 diabetesAppetite control
Weight managementType 2 diabetesMetabolic health
Weight managementMetabolic optimization
Key Risks
NauseaVomitingDiarrheaConstipation
NauseaDiarrheaDecreased appetiteVomiting
NauseaDiarrheaVomiting
StorageRefrigerated (2-8°C)Refrigerated (2-8°C)Refrigerated (2-8°C)
Property comparison · Radar

Profile shape

Duration
Quick Onset
Versatility
Tolerability
Use Cases
Stackability
Typical dose ranges

Dose envelope

For educational purposes only. Consult a healthcare provider before starting any peptide protocol.